CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice
- 1 August 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 42 (2), 420-430
- https://doi.org/10.1002/hep.20784
Abstract
Induction of hepatic phase I/II detoxification enzymes and alternative excretory pumps may limit hepatocellular accumulation of toxic biliary compounds in cholestasis. Because the nuclear xenobiotic receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) regulate involved enzymes and transporters, we aimed to induce adaptive alternative pathways with different CAR and PXR agonists in vivo. Mice were treated with the CAR agonists phenobarbital and 1,4‐bis‐[2‐(3,5‐dichlorpyridyloxy)]benzene, as well as the PXR agonists atorvastatin and pregnenolone‐16α‐carbonitrile. Hepatic bile acid and bilirubin‐metabolizing/detoxifying enzymes (Cyp2b10, Cyp3a11, Ugt1a1, Sult2a1), their regulatory nuclear receptors (CAR, PXR, farnesoid X receptor), and bile acid/organic anion and lipid transporters (Ntcp, Oatp1,2,4, Bsep, Mrp2‐4, Mdr2, Abcg5/8, Asbt) in the liver and kidney were analyzed via reverse‐transcriptase polymerase chain reaction and Western blotting. Potential functional relevance was tested in common bile duct ligation (CBDL). CAR agonists induced Mrp2‐4 and Oatp2; PXR agonists induced only Mrp3 and Oatp2. Both PXR and CAR agonists profoundly stimulated bile acid–hydroxylating/detoxifying enzymes Cyp3a11 and Cyp2b10. In addition, CAR agonists upregulated bile acid–sulfating Sult2a1 and bilirubin‐glucuronidating Ugt1a1. These changes were accompanied by reduced serum levels of bilirubin and bile acids in healthy and CBDL mice and by increased levels of polyhydroxylated bile acids in serum and urine of cholestatic mice. Atorvastatin significantly increased Oatp2, Mdr2, and Asbt, while other transporters and enzymes were moderately affected. In conclusion, administration of specific CAR or PXR ligands results in coordinated stimulation of major hepatic bile acid/bilirubin metabolizing and detoxifying enzymes and hepatic key alternative efflux systems, effects that are predicted to counteract cholestasis. (HEPATOLOGY 2005.)This publication has 42 references indexed in Scilit:
- Molecular Regulation of Hepatobiliary Transport SystemsJournal of Clinical Gastroenterology, 2005
- Complementary Roles of Farnesoid X Receptor, Pregnane X Receptor, and Constitutive Androstane Receptor in Protection against Bile Acid ToxicityOnline Journal of Public Health Informatics, 2003
- Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated miceGastroenterology, 2003
- Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosisJournal of Hepatology, 2003
- Postnatal Expression and Induction by Pregnenolone-16α-Carbonitrile of the Organic Anion-Transporting Polypeptide 2 in Rat LiverDrug Metabolism and Disposition, 2002
- Effects of Ursodeoxycholic and Cholic Acid Feeding on Hepatocellular Transporter Expression in Mouse LiverGastroenterology, 2001
- Molecular Alterations in Hepatocyte Transport Mechanisms in Acquired Cholestatic Liver DisordersSeminars in Liver Disease, 2000
- Molecular Pathogenesis of CholestasisThe New England Journal of Medicine, 1998
- Bile acid profiles in urine of patients with liver diseasesEuropean Journal of Clinical Investigation, 1979
- Sulphated and unsulphated bile acids in serum, bile, and urine of patients with cholestasis.Gut, 1976